SAN DIEGO--(BUSINESS WIRE)--May 18, 2015-- Illumina (NASDAQ:ILMN) announced today that the company has filed a new patent infringement suit against Ariosa Diagnostics, Inc. and its parent company, Roche Molecular Systems, Inc. Illumina is seeking all available remedies.
The new suit, filed in the U.S. District Court for the Northern District of California, is based on Ariosa’s infringement of U.S. Patent No. 7,955,794 (the ‘794 patent), entitled “Multiplex Nucleic Acid Reactions.” The suit is focused on Ariosa’s Microarray-based version of its Harmony™ Prenatal Test.
Illumina and its wholly owned subsidiary, Verinata Health, Inc., previously filed suits in the U.S. District Court for the Northern District of California against Ariosa accusing its Sequencing-based version of the Harmony Prenatal Test of infringing the ‘794 patent and U.S. Patent No. 8,296,076 and U.S. Patent No. 8,318,430. Those previous suits remain pending.
About Illumina
Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the adoption of genomic solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com and follow @illumina.
Forward-Looking Statement for Illumina
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150518006611/en/
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com
